Neurologic and psychiatric complications of antiretroviral agents.
Advances in highly active antiretroviral therapy (HAART) aim to improve the efficacy of HIV drugs as well as the quality of life in HIV-infected patients. Neurologic and psychologic disturbances that occur because of HIV disease and therapy are of great concern, and because they can overlap and are often difficult to distinguish, their pathogenesis is not clearly understood. Furthermore, these complications can lead to decreased adherence, thereby interfering with treatment outcomes. Antiretrovirals, including nonnucleoside reverse transcriptase inhibitors, can penetrate the central nervous system (CNS) and suppress viral replication, but they can also exacerbate CNS side effects and neuropsychiatric symptoms. When deciding which HAART drug combination is most appropriate for a patient, clinicians must consider the individual's risk of CNS complications together with the efficacy of the specific HAART regimen.
Raines
Charles
C
Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, USA.
Radcliffe
Olivia
O
Treisman
Glenn J
GJ
D015526:AIDS Dementia Complex / Q000453:epidemiology / Q000517:prevention & control; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D015897:Comorbidity; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors